Joseph L. Kuti - Concepedia

Author

Joseph L. Kuti

Also Known As

J KUTI, J Kuti, J. Kuti, J. L. Kuti, J.L. Kuti, Joseph Kuti, Joseph L Kuti, Joseph L. Kuti, Joseph L. Kuti,, Joseph Levente Kuti

335

Publications

9.2K

Citations

H-Index

102

Concepts

All Affiliations

Hartford Hospital Hartford Financial Services (United States)University of Connecticut

About

Joseph L. Kuti is an author at Hartford Hospital specializing in medicine, antimicrobial resistance, and pharmacology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Health Sciences	23	31	1.7K
2	Arts	1	1	38
3	Business	1	1	39
4	Education	1	1	38
5	Engineering	1	1	15

Joseph L. Kuti

154

Publications

6.6K

Citations

H-Index

Page 1

	Year	Citations
Clinical Pharmacodynamics of Meropenem in Patients with Lower Respiratory Tract Infections Chonghua Li, Xiaoli Du, Joseph L. Kuti, Antimicrobial Agents and Chemotherapy PharmacotherapyPharmacodynamic ModelingDrug ResistanceAntimicrobial StewardshipRespiratory Infection	2007	291
Use of Monte Carlo Simulation to Design an Optimized Pharmacodynamic Dosing Strategy for Meropenem Joseph L. Kuti, Prachi K. Dandekar, Charles H. Nightingale, The Journal of Clinical Pharmacology	2003	196
Population Pharmacokinetic Analysis and Dosing Regimen Optimization of Meropenem in Adult Patients Chonghua Li, Joseph L. Kuti, Charles H. Nightingale, The Journal of Clinical Pharmacology	2006	166
Randomized, Open-Label, Comparative Study of Piperacillin-Tazobactam Administered by Continuous Infusion versus Intermittent Infusion for Treatment of Hospitalized Patients with Complicated Intra-Abdominal Infection William K. Lau, David F. Mercer, Kamal M.F. Itani, Antimicrobial Agents and Chemotherapy	2006	145
Impact of Extended-Spectrum <i>β</i> -Lactamase–Producing <i>Escherichia coli</i> and <i>Klebsiella</i> Species on Clinical Outcomes and Hospital Costs: A Matched Cohort Study Su Young Lee, Srividya Kotapati, Joseph L. Kuti, Infection Control and Hospital Epidemiology	2006	142
Clinical Efficacy and Pharmacoeconomics of a Continuous‐Infusion Piperacillin‐Tazobactam Program in a Large Community Teaching Hospital Edward M. Grant, Joseph L. Kuti, David P. Nicolau, Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy	2002	127
Clinical Pharmacodynamics of Cefepime in Patients Infected with <i>Pseudomonas aeruginosa</i> Jared L. Crandon, Catharine C. Bulik, Joseph L. Kuti, Antimicrobial Agents and Chemotherapy Antimicrobial ChemotherapyCefepime TherapyBacterial PathogensPharmacodynamic ModelingDrug Resistance	2009	120
Population Pharmacokinetics of High-Dose, Prolonged-Infusion Cefepime in Adult Critically Ill Patients with Ventilator-Associated Pneumonia Anthony M. Nicasio, Robert E. Ariano, Sheryl Zelenitsky, Antimicrobial Agents and Chemotherapy NephrologyPopulation PharmacokineticsPhysiologically-based Pharmacokinetic ModelingCritical Care MedicineRenal Function	2009	119
Population pharmacokinetics and pharmacodynamics of piperacillin/tazobactam in patients with complicated intra-abdominal infection Chonghua Li, Joseph L. Kuti, Charles H. Nightingale, Journal of Antimicrobial Chemotherapy	2005	112
Pulmonary Disposition of Tedizolid following Administration of Once-Daily Oral 200-Milligram Tedizolid Phosphate in Healthy Adult Volunteers Seth T. Housman, J. Samuel Pope, John Russomanno, Antimicrobial Agents and Chemotherapy	2012	102

Page 1